Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720135 · ClinicalTrials.gov registry record · Phase 1
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00720135: Completed Phase 1 study, sponsored by City of Hope Medical Center.
NCT00720135 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720135, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fusion protein cytokine therapy together with rituximab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin lymphoma.
Interventions
- BIOLOGICAL rituximab
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- OTHER flow cytometry
- BIOLOGICAL DI-Leu16-IL2 immunocytokine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT00720135 record still lists
NCT00720135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00720135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720135 about?
NCT00720135 is a clinical study titled "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma". RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spre...
What is the current status of trial NCT00720135?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00720135?
The interventions under investigation include: rituximab (BIOLOGICAL), immunohistochemistry staining method (OTHER), pharmacological study (OTHER), flow cytometry (OTHER), DI-Leu16-IL2 immunocytokine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00720135?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720135's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia